exRNAdisease

General Information

Database ID:

exR0083391

RNA Name:

TNRC6B

RNA Type:

mRNA

Chromosome:

chr22

Starnd:

Coordinate:

Start Site(bp):

40044817

End Site(bp):

40335808

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC009133.6	chr16	29812261	29820092	+
ADCY6	chr12	48766194	48789037	-
AHI1	chr6	135283532	135497765	-

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-let-7a-5p	chr9	94175962	94175983	+
hsa-let-7b-5p	chr22	46113691	46113712	+
hsa-let-7e-5p	chr19	51692793	51692814	+
hsa-miR-129-5p	chr7	128207876	128207896	+
hsa-miR-147a	chr9	120244985	120245004	-
hsa-miR-34a-5p	chr1	9151735	9151756	-
hsa-let-7g-5p	chr3	52268336	52268357	-
hsa-let-7i-5p	chr12	62603691	62603712	+
hsa-miR-140-5p	chr16	69933103	69933124	+
hsa-miR-142-3p	chr17	58331245	58331267	-
hsa-miR-185-5p	chr22	20033153	20033174	+
hsa-miR-206	chr6	52144401	52144422	+
hsa-miR-200a-3p	chr1	1167916	1167937	+
hsa-miR-34c-5p	chr11	111513451	111513473	+
hsa-miR-449a	chr5	55170586	55170607	-
hsa-miR-613	chr12	12764709	12764728	+
hsa-miR-449b-5p	chr5	55170706	55170727	-
hsa-miR-501-3p	chrX	50009772	50009793	+
hsa-miR-502-3p	chrX	50014649	50014670	+
hsa-miR-616-3p	chr12	57519183	57519204	-
hsa-miR-1286	chr22	20249145	20249165	-
hsa-miR-1321	chrX	85835832	85835849	+

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC004687.1	chr17	58330884	58332508	-

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference